Advanced Bifurcation Systems
1451 Quail St. Ste: 104
About Advanced Bifurcation Systems
Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent.
Founder and CMO: Mehran J. Khorsandi
Founder and CTO: Henry Bourang
CEO: Charles A. Laverty
CFO:Ken Richards Vice President of Global Business Development: Drew Foster
12 articles with Advanced Bifurcation Systems
Advanced Bifurcation Systems today announced that the Company has been granted four additional patents, three in the U.S. and one in Europe.
ADVANCED BIFURCATION SYSTEMS FILES PRE-SUBMISSION WITH FDA TO DEFINE CLINICAL PATHWAY; OUTLINES REGULATORY AND CLINICAL STRATEGY FOR EUROPE TO OBTAIN CE MARK
Advanced Bifurcation Systems today announced that the Company has submitted a proposal to the U.S. Federal Drug Administration (“FDA”) for a clinical study leading to an IDE for its bifurcation technology. Concurrently, the Company is defining a regulatory and clinical strategy for Europe to receive a CE mark.
Medical device manufacturer, Advanced Bifurcation Systems® announced today that it has selected a facility in Livermore California for its first manufacturing facility.
Advanced Bifurcation Systems (“ABS” or the “Company”), today announced that ABS, through its wholly-owned Canadian subsidiary, Advanced Bifurcation Systems Canada, Inc. (“ABS Canada”) has been selected to join MaRS Venture Services.
Advanced Bifurcation Systems (ABS), a medical stenting technology company, today announced plans to increase their footprint in Asian markets through partnerships in the region.
Mr. O'Neill is an industry veteran who brings more than 30 years of Board and executive-level experience in the financial markets and medical devices to ABS.
The company has developed a novel technology to overcome limitations in the current approach to bifurcation lesions in coronary angioplasties.
A breakthrough stenting technology is being developed by ABS and with 34 patents in place to protect their intellectual property it would be hard to bet against them.
Advanced Bifurcation Systems Announces Scott King Joins as Chief of Compliance Ahead of FDA Application
ABS Scott King has joined the leadership team as VP of Regulatory Affairs.
The new goal was announced in conjunction with the appointment of new CFO Ken Richards, who brings with him a strong background in both debt and equity financing.
Advanced Bifurcation Systems is developing a new procedure that could potentially eliminate the need for open-heart surgery in thousands of patients every year.